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Background: Surgeons have traditionally been reluctant to perform total pancreatectomy because of
concerns for brittle diabetes and poor quality of life (QoL). Several recent studies have suggested that
outcomes following total pancreatectomy have improved, but a systematic review is lacking.
Methods: A systematic review was undertaken of studies reporting on outcomes after total pancreate-
ctomy for all indications, except chronic pancreatitis. PubMed, EMBASE (Ovid), and Cochrane Library
were searched (2005–2018). Endpoints included functional outcome and QoL.
Results: A total of 21 studies, including 1536 patients, fulfilled the eligibility criteria. During a
median follow-up of 20⋅8 (range 1⋅5–96⋅0)months, 18⋅6 per cent (45 of 242 patients) were readmit-
ted for endocrine-related morbidity, with associated mortality in 1⋅6 per cent (6 of 365 patients). No
diabetes-related mortality was reported in studies including only patients treated after 2005. Symptoms
related to exocrine insufficiency were reported by 43⋅5 per cent (143 of 329 patients) during a median
follow-up of 15⋅9 (1⋅5–96⋅0)months. Overall QoL, reported by 102 patients with a median follow-up
of 28⋅6 (6⋅0–66⋅0)months, using the EORTC QLQ-C30 questionnaire, showed a moderately reduced
summary score of 76 per cent, compared with a general population score of 86 per cent (P= 0⋅004).
Conclusion: Overall QoL after total pancreatectomy is affected adversely, in particular by the consider-
able impact of diarrhoea that requires better treatment. There is also room for improvement in the man-
agement of diabetes after total pancreatectomy, particularly with regards to prevention of diabetes-related
morbidity.
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Introduction
The most common indication for total pancreatectomy is
pancreatic cancer, but total pancreatectomy is increasingly
performed for main-duct/mixed-type intraductal papillary
mucinous neoplasm (IPMN)1–3. Total pancreatectomy for
IPMN requires extensive counselling, as this is prophy-
lactic surgery. Other indications for total pancreatectomy
could be multifocal pancreatic disease (such as neuroen-
docrine tumours and renal cell cancer metastases) and
technical difficulties, or patients with a very high risk of
having a pancreatic anastomosis (for instance in arterial
reconstruction)4–6.
Most surgeons have traditionally been reluctant to
perform total pancreatectomy because of the associated
postoperative morbidity and resulting lifelong insulin-
dependent brittle diabetes, with risk of severe hypogly-
caemia and substantial impact on quality of life (QoL).
In recent years, several investigators have suggested
that the role of total pancreatectomy in IPMN should be
expanded as the postoperative management has improved7.
Of note, a recent international survey8 showed no con-
sensus on the use of total pancreatectomy in patients
with main-duct/mixed-type IPMN. This lack of con-
sensus is likely to be related to concerns regarding total
pancreatectomy-related diabetes and exocrine insuffi-
ciency. Others1,4 have questioned whether any indication
remains for an upfront total pancreatectomy in the current
era of improved imaging.
Knowledge of long-term functional (endocrine and
exocrine insufficiency) outcomes and QoL after total
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pancreatectomy is therefore essential during preoperative
counselling and shared decision-making. This systematic
review focuses on short- and long-term functional out-
comes after total pancreatectomy, and its impact on QoL.
Methods
This systematic review was registered with PROSPERO
(registration number CRD420016051093)9 and performed
in accordance with the PRISMA guidelines10.
Search strategy
A systematic literature search was conducted in PubMed,
EMBASE (Ovid), and the Cochrane Library for stud-
ies published from 1 January 2005 to 31 January 2018.
This inclusion period was chosen because management
of endocrine and exocrine insufficiency seems to have
improved in recent years11. The main search term was
‘total pancreatectomy’. The full search strategy is shown in
Table S1 (supporting information). Restrictions on English
language and studies older than 13 years (arbitrary cut-
off) were applied. After excluding duplicates, studies were
screened by two authors independently, according to the
eligibility criteria by title, abstract and full text. The final
decision on eligibility was made by consensus.
Eligibility criteria
Studies of at least ten patients reporting on functional
outcomes and QoL after total pancreatectomy were con-
sidered eligible. Studies or subgroups where more than
10 per cent of patients had undergone total pancreatec-
tomy for chronic pancreatitis were excluded unless results
were given separately. Benign indications with no further
description were considered as chronic pancreatitis. Con-
ference abstracts and review articles were also excluded.
When there were overlapping cohorts, only unique results
were used. If there were overlapping outcomes between
these cohorts, the largest study was chosen for analysis.
Definitions
Total pancreatectomy was defined as removal of the entire
pancreas, with or without splenectomy, performed via
either an open or minimally invasive technique. Primary
total pancreatectomy was defined as elective total pancre-
atectomy (planned before surgery as well as decided dur-
ing the operation), and emergency total pancreatectomy as
surgery performed as a result of trauma. Urgent comple-
tion total pancreatectomy was defined as emergency total
pancreatectomy for postoperative complications after pan-
creatoduodenectomy, whereas elective completion total
pancreatectomy was performed mostly for recurrence in
the remnant pancreas.
Endocrine insufficiency was defined as diabetes after
total pancreatectomy, classified by the WHO12 and the
American Diabetes Association13 as one of the causes of
pancreatogenic (type 3c) diabetes. Exocrine insufficiency
was defined as inadequate pancreatic enzyme function,
with or without related symptoms, that required enzyme
substitution.
Where only readmissions were reported, these were
not defined as complications to avoid underestimation of
diabetes-related morbidity. Invasive or malignant IPMNs
were grouped under carcinomas as ‘invasive IPMN’.When
studies did not report the grade of dysplasia, the IPMNs
were grouped as ‘potentially malignant’.When studies pre-
sented only the minimum duration of follow-up, that value
was chosen to calculate the pooled weightedmedian.When
studies presented the maximum follow-up or the range, the
half of this value was used to calculate the pooled weighted
median. The postoperative period was defined as a maxi-
mum of 90 days after surgery.
Extracted data
The following data were extracted per study by two
authors: first author, country, year of publication, study
design, age, sex, diagnosis/indication for surgery, dura-
tion of follow-up, number of patients undergoing total
pancreatectomy, and outcomes of exocrine and endocrine
insufficiency and QoL. Two authors cross-checked all data
independently. Corresponding authors of the included
studies were contacted where there was missing or insuffi-
cient data. The European Organization for Research and
Treatment in Cancer Quality of Life Questionnaire Can-
cer (EORTC QLQ-C30) global health status, functioning
and symptom scores were determined, and differences with
the general population calculated. Clinically important
differences were categorized and defined according to
Osoba et al. 14: less than 5 per cent, no change; 5–10 per
cent, a little change; 10–20 per cent, moderate change;
more than 20 per cent, very much change.
Quality assessment
The methodological quality of the included studies
was assessed by two authors independently, using the
Newcastle–Ottawa Scale (NOS)15. Methodological qual-
ity was scored for ‘selection of patients’, ‘comparability’
and ‘outcome of study participants’, and was ranked with a
maximum of 5 points. In this systematic review, the parts
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Fig. 1 PRISMA diagram for the systematic review
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of the NOS score (‘selection of the non-exposed’, ‘out-
come of interest’ and ‘comparability’) were not applicable,
because of its descriptive nature. In this study, cohort
studies with a NOS score of 5 or higher were considered
of high quality.
Statistical analysis
Age, length of follow-up and QoL parameters from the
different questionnaires are presented as mean(s.d.) and
median (range) values. Categorical data are presented as
frequencies and percentages. Overall follow-up values are
presented as pooled weighted median. When included
studies reported median (range) values, means(s.d.) val-
ues were calculated using statistical algorithms accord-
ing to the method of Wan and colleagues16 and Hozo
and co-workers17. P< 0⋅050 was considered statistically
significant. Statistical analysis was performed using SPSS
version 24 (IBM, Armonk, New York, USA).
Results
The systematic search (Table S1, supporting information)
identified 21 eligible studies, all cohort studies, comprising
1536 patients undergoing total pancreatectomy2,6,18–36.
The PRISMA diagram of studies included in this sys-
tematic review is presented in Fig. 1. Most patients were
men (52⋅6 per cent), and the median age was 65 years; the
methodological quality was scored as high in 20 of the 21
studies (Table S2, supporting information).
Surgical details
Of 1536 patients, indication for total pancreatectomy was
pancreatic ductal adenocarcinoma (PDAC) in 806 patients
(52⋅5 per cent) and IPMN in 454 patients (29⋅6 per cent);
IPMN consisted of 227 patients (14⋅8 per cent) with
non-invasive IPMN and 227 (14⋅8 per cent) with invasive
IPMN (Table 1).
In 1254 patients (81⋅6 per cent), the type of total pancre-
atectomy (primary versus completion pancreatectomy) was
described. Primary total pancreatectomy was performed in
1120 patients (89⋅3 per cent), of whom 1117 (99⋅7 per cent)
had elective surgery and three (0⋅3 per cent) had emergency
surgery. Completion total pancreatectomy was performed
in 134 patients (10⋅7 per cent), electively in 110 (82⋅1 per
cent) and as an emergency in 24 (17⋅9 per cent).
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Table 1 Diagnosis in patients who had a total pancreatectomy
Non-carcinomas
Reference n Carcinomas Potentially malignant Benign CP* Other
Barbier et al.18 56 PDAC (4) IPMN (20) – 1 (2) Renal mets (2)
Invasive IPMN (22) NET (6)
Acinar cell carcinoma (1)
Casadei et al.19† 20 PDAC (7) IPMN (2) – 1 (5) Renal mets (2)
Invasive IPMN (6) NET (2)
Casadei et al.20† 73 PDAC (38) IPMN (15) – 2 (3)§ Mets (3)
Periampullary cancer (3) NET (6)
Other (5)
Serous cystic tumours (1)
Crippa et al.21† 65 PDAC (19) IPMN (6) SCA (1) 1 (2) Renal mets (6)
Invasive IPMN (25) NET (6)
Periampullary cancer (1)
Crippa et al.22†‡ 29¶ Invasive IPMN (13) IPMN (16) – 0 (0) –
Epelboym et al.23 77 PDAC (50) IPMN (15) SCA (1) 4 (5)§ Renal mets (1)
Invasive IPMN (2) NET (4)
Fujino et al.24 36 PDAC (17) NET (2) Acute pancreatitis (1) 1 (3) Mets (1)
Invasive IPMN (14)
Hartwig et al.6 434 PDAC (289) IPMN (44) SCN (4) 4 (0⋅9)§ Other (4)
Invasive IPMN (31) NET (28)
Adenosquamous
carcinoma (8)
Acinar cell carcinoma (4)
Other (18)
Hata et al.25 43 PDAC (21) IPMN (11) Solid pseudopapillary
neoplasm (1)
1 (2) Mets (3)
NET (2) SCN (1)
AVM (3)
Jamil et al.26 14 IPMN (9) IPMN (5) – 0 (0) –
Kitagawa et al.27 10 Carcinoma (4) IPMN (5) Gastrinoma (1) 0 (0) –
Müller et al.2‡ 147 PDAC (78) IPMN (12) Cystic tumours (5) 13 (8⋅8) Renal mets (9)
Invasive IPMN (10) NET (11)
Periampullary cancer (7)
Cystic tumour (2)
Nikfarjam et al.28 15 Adenocarcinoma (13) IPMN (1) Cystadenoma (1) 0 (0) –
Parsaik et al.29‡ 97 PDAC (49) Cystic neoplasm (7) – 0 (0) Other (14)
Invasive IPMN (24)
Periampullary
adenocarcinoma (3)
Reddy et al.30 100 PDAC (100) – – 0 (0) –
Shi et al.31 52 PDAC (43) – – 0 (0) Renal mets (1)
Invasive IPMN (4)
Adenosquamous
carcinoma (1)
Acinar adenocarcinoma (1)
Cystadenocarcinoma (2)
Stauffer et al.32 47 PDAC (10) IPMN (21) – 2 (4) Renal mets (1)
Invasive IPMN (10) NET (1) Trauma (1)
Cholangiocarcinoma (1)
Suzuki et al.33 41 PDAC (13) IPMN (5) – 0 (0) Renal mets (2)
Invasive IPMN (20) Intraductal tubulopapillary
neoplasm (1)
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Table 1 Continued
Non-carcinomas
Reference n Carcinomas Potentially malignant Benign CP* Other
Takami et al.34‡ 33 PDAC (25) IPMN (7) – 1 (3)§ –
Watanabe et al.35 44 PDAC (20) IPMN (2) – 1 (2)§ Renal mets (1)
Invasive IPMN (18) NET (1)
Distal cholangiocarcinoma
(1)
Zakaria et al.36 103 PDAC (23) IPMN (40) Ampullary adenoma with
IPMN (1)
8 (7⋅8) Renal mets (1)
Invasive IPMN (19) NET (7)
Ampullary
adenocarcinoma (1)
Trauma (1)
Cholangiocarcinoma (1)
Sarcoma (1)
Overall* 1536 1106 (72⋅0) 312 (20⋅3) 20 (1⋅3) 40 (2⋅6) 58 (3⋅8)
*Values in parentheses are percentages. †No overlapping cohorts; used unique results and the biggest group in case of non-unique results; ‡subgroup used;
§benign tumours (possible chronic pancreatitis (CP)); ¶after contacting author. PDAC, pancreatic ductal adenocarcinoma; IPMN, intraductal papillary
mucinous neoplasm; NET, neuroendocrine tumour; mets, metastases; SCA, serous cystadenoma; SCN, serous cystic neoplasm; AVM, arteriovenous
malformation.
Endocrine insufficiency
Outcomes related to endocrine insufficiency
after total pancreatectomy were reported in 19
studies2,6,18–24,26–33,35,36, including 809 patients, after
a median follow-up of 20⋅8 (range 1⋅5–96⋅0)months. The
endocrine-related morbidity rate was 25⋅9 per cent (112
of 432 patients). Ten studies18–24,32,33,35, including 299
patients, reported the number of prescribed insulin units
per day (mean 27 units/day). Mean(s.d.) HbA1c levels at
6 and 12months after surgery were 7⋅5(0⋅5) and 7⋅2(0⋅7)
per cent respectively24,26,31–33. Two studies31,33 found an
increase in HbA1c concentration during the first 3months
after surgery, although stabilization was seen afterwards.
During the first year after surgery, HbA1c levels were
increased in both benign and malignant diseases, after
which the levels remained stable at acceptable levels6. For
endocrine-related reasons, 45 of 242 patients (18⋅6 per
cent) were admitted to hospital2,18,19,21,23,26,27,32,35.
Two studies21,29 reported on long-term diabetes-related
complications. Crippa and colleagues21 reported long-term
diabetes-related complications in six of 45 patients after
total pancreatectomy (follow-up at least 60months),
including peripheral vascular disease (4 patients), stroke
(1) and retinopathy (1). During a median follow-up of
2 years, Parsaik et al29. found development of target organ
complications in seven of 26 patients.
Nine studies2,18,19,21,22,24,31,32,35 described diabetes-
related mortality, which occurred in six of 365 patients (1⋅6
per cent). Three patients died from hypoglycaemia, two
after 8 and 22months, and one patient at an unknown time
during a median follow-up of 35 (range 4–168)months.
Two patients died from ketoacidosis, one patient after
5months and the other at an unknown time during a
median follow-up of 21 (2–222)months. Hyperglycaemia
was the cause of death in one patient 17 days after surgery.
In addition, diabetes-related mortality was 0 per cent (0
of 94 patients) in the most recent series, comprising the
studies that included patients treated after 200519,22,31
(Table 2).
Exocrine insufficiency
Outcomes related to exocrine insufficiency were reported
in 15 studies2,6,18,19,21,24–27,29,31–35, including 495
patients, during a median follow-up of 19⋅6 (range
1⋅5–96⋅0)months (Table 3). Exocrine insufficiency-related
symptoms were reported by 43⋅5 per cent (143 of
329 patients) during a median follow-up of 15⋅9
(1⋅5–96⋅0)months. Among 136 patients receiving pancre-
atic enzyme substitution, 32 (23⋅5 per cent) still reported
symptoms18,21,33,35. In general, the most common symp-
tom was diarrhoea, which occurred in 0–64 per cent of
the patients2,18,21,33–35. Steatorrhoea was described by
two studies21,26, varying between 14 and 27 per cent of
patients. Ten studies18,19,21,24,27,29,32–35 reported on loss of
bodyweight after surgery, with an occurrence of 44–85
per cent of the patients and a median loss of 6⋅7 (range
3⋅1–15) kg. Shi and co-workers31 observed stabilization of
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Table 2 Endocrine insufficiency in patients who had a total pancreatectomy
Reference n
Follow-up
(months)*
Insulin
(units/day)*
Glycaemic
events/week* Complications Hospitalization Mortality
Barbier et al.18 52 35 (4–168) R: 21 (7–70) n.r. n.r. Hypoglycaemic
coma (6)
Ketoacidosis (1)
L: 16 (7–48) Hypoglycaemia (1)
Insulin pump
(n=1)
Subgroup 25 66 (7–168) n.r. 10 (1–36)/month Loss of consciousness
due to hypoglycaemia
(10)
Diabetes
equilibration (14)
n.r.
Casadei et al.19 13 23 (6–60) R: 18 (0–18) 4 (1–10)
hypoglycaemia
and
hyperglycaemia
n.r. Poor glycaemic
control (3)
Severe
hypoglycaemia (0)
L: 7 (4–20)
Casadei et al.20 35 >1 year R: 7 (0–18) n.r. n.r. n.r. n.r.
I: 3 (0–19)
L: 19 (4–40)
Crippa et al.21 45 2–14 years 32 (18–52) 2 (0–5) PVD (4) Hyperglycaemia
(3)
Hypoglycaemia (0)
Stroke (1) Hypoglycaemia
(7)
Retinopathy (1)
Crippa et al.22 29 62 (6–91) n.r. n.r. n.r. n.r. Insulin-related coma
(0)
Subgroup 15 63 (30–91) R: 25 (19–38) n.r. Severe hypoglycaemia
(7)
n.r. n.r.
L: 4 (0–14)
Epelboym et al.23 17 40⋅3 (i.q.r. 32⋅8) 29⋅8(18⋅6)† 2 (i.q.r. 2) Hypoglycaemic
episodes (16)
Hypoglycaemic
episodes (4)
n.r.
Fujino et al.24 36 n.r. 22(6)† n.r. n.r. n.r. Severe
hypoglycaemia (2)
Hartwig et al.6 83 ≥1 year n.r. n.r. n.r. n.r. n.r.
Jamil et al.26 14 Up to 24 Insulin pump
(n=3)
n.r. Hypoglycaemic
episodes (7)
Hypoglycaemia
(1)
n.r.
Hyperglycaemia
(0)
Kitagawa et al.27 10 7⋅9 (2⋅1–28⋅6) 0⋅45(0⋅13)
units/kg/day‡
at discharge†
n.r. n.r. Hypoglycaemia
(1)
n.r.
Müller et al.2 47 >6 after surgery n.r. n.r. n.r. Hyperglycaemia
(4)
Mortality (0)
Hypoglycaemia
(3)
Nikfarjam et al.28 15 Postoperative
period
n.r. n.r. Hypoglycaemia (4) n.r. n.r.
Parsaik et al.29 26 2 (i.q.r.
0⋅6–5⋅3) years
n.r. n.r. Mild hypoglycaemic
episodes (19)
n.r. n.r.
Severe hypoglycaemic
episodes (7)
Target organ
complications (7)
Reddy et al.30 100 Postoperative
period
n.r. n.r. Glycaemic control: CD
I (20), CD IV (1)
n.r. n.r.
Shi et al.31 52 To 12months
after surgery
0⋅56(0⋅12)
units/kg/day‡ at
12months†
n.r. n.r. n.r. Hypoglycaemia or
diabetic
complications (0)
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Table 2 Continued
Reference n
Follow-up
(months)*
Insulin
(units/day)*
Glycaemic
events/week* Complications Hospitalization Mortality
Stauffer et al.32 47 Postoperative
period
L: 10 (0–80) at
discharge
n.r. Major glycaemic
events (2)
n.r. Hyperglycaemia (1)
Subgroup 46 To 12months
after surgery
n.r. n.r. n.r. Glycaemic events
(5)
n.r.
Suzuki et al.33 41 To 12months
after surgery
30 (12–50) n.r. n.r. n.r. n.r.
0⋅56(0⋅16)
units/kg/day at
12months†
Watanabe et al.35 44 21 (2–222) n.r. n.r. n.r. n.r. Ketoacidosis (1)
Subgroup 25 22 (2–73) R: 17 (10–28) 2 (1–4) (12
patients)
Loss of consciousness
(0)
Hyperglycaemia
or hypoglycaemia
(0)
n.r.
L: 6 (0–16)
Zakaria et al.36 103 Postoperative
period
n.r. n.r. Major glycaemic event
(6)
n.r. n.r.
Overall¶ 809 20⋅8months§ 26†§ 2⋅3 (2–4)
(125 patients)§
112 of 432 (25⋅9) 45 of 242 (18⋅6) 6 of 365 (1⋅6)
R: 16
L: 12
Values are *median (range) and †mean(s.d.). ‡Not used in the analysis. §Weighted average of medians. ¶Values in parentheses are percentages unless
indicated otherwise. R, rapid-acting insulin; n.r., not reported; L, long-acting insulin; I, intermediate-acting insulin; PVD, peripheral vascular disease; CD,
Clavien–Dindo co-morbidity grade.
postoperative weight loss after 6–12months of follow-up.
One study33 reported the dosages of pancreatic enzymes
during the first year after operation and revealed that
patients needed higher dosages as time progressed. In that
study, pancreatic enzyme dosage was based on patients’
stool consistency, BMI, serum albumin and signs of liver
steatosis on CT, achieving a stabile BMI and no diarrhoea.
Several studies6,18,24,25,31,33,34 investigated laboratory tests
to assess patients’ nutritional status. Serum nutritional
markers decreased in the first 1–6months after total pan-
createctomy, but had stabilized or normalized by 12months
after surgery6,24,31,33,34. Barbier and colleagues18 showed
that, also in the long term, prealbumin and albumin levels
remained stabile within normal ranges.
Hata et al.25 investigated long-term consequences by
describing development of hepatic steatosis in 16 of 43
patients, which was associated with poor nutritional sta-
tus early after surgery. None of these patients developed
liver cirrhosis or liver failure during long-term follow-up.
Suzuki and co-workers33 suggested that all patients tended
to develop hepatic steatosis at 1 year after surgery, but signs
of steatosis decreased by enhancing the dose of pancreatic
enzymes. Liver function also remained normal in the long
term (median follow-up 66months), according to Barbier
et al.18.
Quality of life
QoL after total pancreatectomy for all indications was
reported in seven studies2,6,18–20,23,35, including 243
patients, using various validated questionnaires. The
median weighted follow-up in these studies was 28⋅6 (range
6⋅0–66⋅0)months. The following questionnaires were
used: EORTC QLQ-C30 (5 studies2,6,18,19,23), EORTC
QLQ after pancreatic resection (EORTC QLQ-PAN26)
(3 studies)6,18,23, Audit of Diabetes Dependent Quality of
Life (ADD-QoL) (1 study23), Short Form 36 (SF-36) (1
study35), Problem Areas in Diabetes scale (PAID20) (1
study20) and EQ-5D-5L (1 study20).
The EORTC QLQ-C30 questionnaire, designed to
measure overall health status in patients with cancer37,
was used in four studies2,18,19,23, including 102 patients.
One study6 with 81 patients was excluded for this analysis,
because EORTC QLQ-C30 scores were shown only
in figures and no exact data were available. The mean
global health status score was 64 per cent, a small clin-
ically important difference (58–69 per cent) compared
with the general population score of 71 per cent (Table 4).
Mean scores in the functioning scales varied from 67 to
78 per cent and, compared with the general population
scores, they varied from 9 per cent (little change) to
14 per cent (moderate change). Global health status and all
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Table 3 Exocrine insufficiency in patients who had a total pancreatectomy
Weight loss
Reference n
Follow-up
(months)*
Pancreatic lipase
(units/day)*
Symptoms and
related readmissions No. of patients kg*
Barbier et al.18 25 66 (7–168) 150 000
(75 000–450 000)
Diarrhoea (6) 15 9 (2–14)
6 (3–18) capsules
Casadei et al.19 13 23 (6–60) 8 (6–11) capsules n.r. 11 15 (1–32)
Crippa et al.21 45 2–14 years 80 000
(30 000–160 000)
Steatorrhoea (12) 20 5 (1–18)
Diarrhoea (6)
Fujino et al.24 n.r. >12 n.r. n.r. n.r. 8⋅8(10⋅4)%
Hartwig et al.6 75 ≥1 year n.r. n.r. n.r. n.r.
Hata et al.25 43 >6 18 patients: high dose
(1800mg/day)
Hepatic steatosis (16) n.r. n.r.
Pancrelipase within
2weeks of TP
Jamil et al.26 14 ≥24 n.r. Steatorrhoea because of
intolerance to medication (1)
n.r. n.r.
Inadequate dosing (1)
Kitagawa et al.27 10 7⋅9 (2⋅1–28⋅6) n.r. Readmission because of
diarrhoea (1)
n.r. 4⋅1†
Use of antidiarrhoeal drugs (4)
Müller et al.2 47 >6 n.r. Flatulence (28) n.r. n.r.
Diarrhoea (30)
Parsaik et al.29 26 2 (i.q.r. 0⋅6–5⋅3) years n.r. n.r. n.r. 3⋅1(0⋅54)†
Shi et al.31 52 To 12months after
surgery
n.r. n.r. n.r. n.r.
Stauffer et al.32 46 To 12months after
surgery
n.r. Readmission because of
malnutrition, failure to thrive,
nausea, vomiting, diarrhoea or
weakness (20)
n.r. 8⋅8 (1⋅2–39⋅5)
Suzuki et al.33 41 To 12months after
surgery
125 145(97 487) at
12months†
Diarrhoea (0) 18 4⋅23
Takami et al.34 33 Early postoperative
period
n.r. Severe diarrhoea (10) n.r. >10% at 6months
Dumping syndrome (0)
Watanabe et al.35 25 22 (2–73) 150 000 (0–225000) Diarrhoea (8) 17 4⋅5 (1–15)
Overall‡ 495 19⋅6‡ 143 of 329 (43⋅5) 81 of 149 (54⋅4) 6⋅7 (3⋅1–15)‡
Values are *median (range) and †mean(s.d.); ‡values in parentheses are percentages. ‡Weighted average of medians. n.r., Not reported; TP, total
pancreatectomy.
functioning domains differed significantly in comparison
with those for the general population. Mean scores in the
symptom scales varied from 6 to 38 per cent, with fatigue,
dyspnoea and especially diarrhoea as the main symptoms.
Long-term QoL was evaluated in 81 patients by Hartwig
and colleagues6, using the EORTC QLQ-C30. After
matching data with an age- and sex-matched healthy con-
trol population, no differences in global health status were
found. During the first year after surgery, global health sta-
tus was significantly lower in patients with benign disease,
but no differences between benign and malignant disease
were seen after this time. Patients with malignant disease
suffered significantly more from diarrhoea than those with
benign disease, compared with the control population.
The EORTC QLQ-PAN26 questionnaire, designed
to evaluate disease symptoms, treatment side-effects and
emotional issues specific to pancreatic cancer, was used
in three studies6,18,23 (67 patients). The most frequently
described symptom was altered bowel habit.
One study35 with 25 patients used the SF-36, a question-
naire that evaluates eight domains of physical and mental
well-being. The physical aspects of QoL were signifi-
cantly lower than those in the national population (which
included many young people) (P< 0⋅050). In addition,
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Table 4 Quality of life assessed with the EORTC QLQ-C30 questionnaire
Barbier
et al.18
(n=25)¶
Casadei
et al.19
(n=13)
Epelboym
et al.23
(n=17)
Müller
et al.2
(n=47)
Total
(n=102)
General
population38
(n=7802) P#
Clinically
relevant
difference (%)14
Global health status* 64(4) 58(21) 69(n.r.) n.r. 64(13) 71(22) 0⋅019 7 (low)
Functioning scales† n.r. n.r. 79(n.r.) n.r. 79 n.r.
Physical 84(3) 65(25) n.r. n.r. 78(17) 90(16) <0⋅001 12 (moderate)
Role 75(2) 67(25) n.r. n.r. 72(15) 85(25) 0⋅001 13 (moderate)
Emotional 76(3) 67(21) n.r. 63(24) 67(11) 76(23) <0⋅001 9 (low)
Cognitive 76(2) 75(25) n.r. n.r. 76(15) 86(20) 0⋅002 10 (moderate)
Social 73(2) 75(25) n.r. n.r. 74(15) 88(23) <0⋅001 14 (moderate)
Symptom scales‡ n.r. n.r. 18(n.r.) n.r. 18 n.r.
Fatigue 38(3) 39(22) n.r. n.r. 38(13) 24(24) <0⋅001 14 (moderate)
Nausea and vomiting 15(2) 17(17) n.r. n.r. 16(10) 4(12) <0⋅001 12 (moderate)
Pain 26(2) 21(21) n.r. n.r. 24(13) 21(28) 0⋅509 3 (none)
Dyspnoea 19(1) 42(25) n.r. n.r. 27(18) 12(23) <0⋅001 15 (moderate)
Insomnia 20(1) 42(25) n.r. n.r. 28(18) 22(30) 0⋅218 6 (low)
Appetite loss 13(1) 25(25) n.r. n.r. 17(16) 7(18) <0⋅001 10 (moderate)
Constipation 9(1) 8(8) n.r. 4⋅2(17) 6(13) 7(18) 0⋅646 1 (none)
Diarrhoea 25(1) 33(17) n.r. n.r. 28(11) 7(18) <0⋅001 21 (high)
Financial difﬁculties 16(1) 0(0) n.r. n.r. 11(8) 10(23) 0⋅789 1 (none)
EORTC QLQ-C30 summary score§ 78 71 n.a. n.a. 76 86 0⋅004 11 (moderate)
Values are mean(s.d.). n.r., Not reported; n.a., not applicable. *The higher the score, the better the global health status; †the higher the score, the better
the functioning; ‡the higher the score, the greater the symptoms. §(Physical functioning + Role functioning + Social functioning + Emotional function-
ing + Cognitive functioning + (100−Fatigue)+ (100−Pain)+ (100 – Nausea and Vomiting)+ (100 – Dyspnoea)+ (100 – Insomnia)+ (100 – Appetite
loss)+ (100 – Constipation)+ (100 – Diarrhoea))/13. ¶Data received from corresponding author. #Student’s t test.
scores of vitality and mental well-being were significantly
worse in patients with diarrhoea-related complaints.
However, QoL was comparable with that in age-matched
controls. These authors concluded that QoL after total
pancreatectomy is acceptable if the patient is capable of
self-management.
Diabetes-specific quality of life
Epelboym and colleagues23 assessed the impact of diabetes
on theQoL in 17 patients after total pancreatectomy and in
eight patients following pancreatoduodenectomy. Insulin
was used in all patients in the total pancreatectomy group
versus half of those in the pancreatoduodenectomy group.
All average weighted scores, measured by the ADD-QoL
questionnaire, did not differ significantly between the
groups. However, leisure time and physical activity were
lower in patients after total pancreatectomy. These authors
concluded that total pancreatectomy-induced diabetes has
a negative impact on functioning and activities, and that
overall QoL is comparable with that in patients who have
had a pancreatoduodenectomy.
One study20 used the PAID20 questionnaire in 35
patients after total pancreatectomy and in 43 after pan-
creatoduodenectomy, and did not find any significant
differences, except for the question about feelings of guilt
or anxiety about their diabetes management when glu-
cose values were off-track. These authors concluded that
diabetes after total pancreatectomy is manageable, with
acceptable QoL.
Quality of life after pancreatoduodenectomy versus total
pancreatectomy
Two studies20,23 compared QoL after total pancrea-
tectomy with that following pancreatoduodenectomy.
Epelboym et al.23 performed a matched-paired analy-
sis of age, postoperative pathology, and preoperative
and postoperative presence of diabetes. After a median
follow-up of 45months, patients in both groups had
similar functional and symptom scales and global health
status. Overall QoL after total pancreatectomy was
good, and showed no significant difference from that in
patients who had a pancreatoduodenectomy, according
to Casadei and colleagues20. Diabetes impacted poorly
on QoL in both groups, but the overall PAID20 score
tended to favour pancreatoduodenectomy (P= 0⋅081).
Nevertheless, Casadei et al.20 concluded that overall QoL
and the impact of diabetes after total pancreatectomy
were acceptable, and comparable with those following
pancreatoduodenectomy.
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Discussion
This systematic review of 1536 patients after total pan-
createctomy has shown that, over a follow-up period of
20⋅8months, endocrine-related readmission was fairly
common (18⋅6 per cent) and should be improved.
Diabetes-related mortality (1⋅6 per cent) did occur,
but only in patients treated before 2005. The burden
of diarrhoea seems to be significant, with a negative
impact on QoL, requiring accurate personalized manage-
ment. Although overall QoL appears acceptably reduced
after total pancreatectomy, data are sparse as few stud-
ies have reported on long-term endocrine and exocrine
insufficiency and QoL.
Most surgeons favour partial over total pancreatectomy
in order to prevent the consequences of insulin-dependent
diabetes and its effects on QoL. Based on this infor-
mation, new-onset diabetes after total pancreatectomy
seems similar to type 1 diabetes mellitus26,39,40. Mul-
tiple studies2,20,26,35,39,41 concluded that diabetes after
total pancreatectomy could be managed well, whereas
others18,19 still emphasized its complexity. The present
review revealed a substantial rate of diabetes-related mor-
bidity, but nevertheless acceptable and stabilized levels of
HbA1c in the first year after surgery, indicating reasonable
management. All diabetes-related mortality occurred in
studies that included patients between 1990 and 2013.
More recent studies, which included patients treated only
after 2005, did not report any diabetes-related mortality
at all. Hence, brittle diabetes may no longer be a correct
term in current practice of total pancreatectomy, owing to
improved diabetes management.
Diarrhoea was the most frequently reported symptom
after total pancreatectomy; 23⋅5 per cent of patients still
had symptoms despite pancreatic enzyme substitution. The
wide range of incidence of diarrhoea (0–64 per cent) sug-
gests that management is difficult, but achievable. In the
literature6,18,25, the extent of resection is mentioned as a
contributing cause of diarrhoea. Extended resection could
lead to autonomic denervation and therefore impaired
bowel control, explaining the difference in severity of diar-
rhoea between benign and malignant indications2,6. Nev-
ertheless, the potential for sufficient stool management
and improvement of nutritional status over time suggests
a crucial role for extensive patient education and follow-up
to optimize pancreatic enzyme replacement therapy18,33,42.
Moreover, optimal nutritional status seems to be important
to reduce the risk of hepatic steatosis25,33. In 1991, Dresler
et al.43 found that three of 49 patients died as consequence
of liver cirrhosis, but cirrhosis was no longer seen in recent
literature.
In this review, QoL was reduced significantly in 11 of 15
domains in comparison with that in the general population.
Decreases in global health status and functioning were
classified as small and moderate, indicating a reasonable
reduction. Specifically, two studies6,35 compared QoL with
age- and/or sex-matched healthy individuals and found
no significant differences during a median follow-up of
22 (range 2–73)months and up to 5 years respectively.
Other studies, including some not in the present sys-
tematic review, described impaired but still acceptable
QoL, and even comparability with other types of diabetes
and partial pancreatectomy2,18,20,23,40,41,44,45. Whereas the
impact of diabetes on QoL is suggested to be compa-
rable with that of partial pancreatoduodenectomy20,23,
several articles2,6,18,35 mentioned the major impact of
diarrhoea.
The current state of knowledge about functional out-
comes after total pancreatectomy and its impact on QoL
seems to be limited, and a variety of opinions exist con-
cerning the acceptability of outcomes. Nevertheless, recent
studies1,18,36 have shown an increase in total pancreate-
ctomy performed over time, especially in patients with
IPMN. In the present review, however, the majority of
patients (52⋅5 per cent) underwent total pancreatectomy
for PDAC and 29⋅6 per cent for IPMN. Despite the poten-
tial benefits of total pancreatectomy as radical treatment for
IPMN, international consensus regarding the role of total
pancreatectomy is lacking, possibly as result of limited data
on functional outcomes, QoL and long-term survival rates
compared with those for partial pancreatectomy8.
This review should be interpreted in the light of some
shortcomings. First, the heterogeneity between studies was
substantial, mainly because of different indications for total
pancreatectomy. Second, follow-up periods varied (from
1month to several years). Long-term follow-up was lim-
ited, and therefore data on long-term consequences of total
pancreatectomy are sparse. In addition, one-third of all
included studies made no distinction between elective and
emergency total pancreatectomy. Potentially, outcomes of
(completion) total pancreatectomy in emergency settings
may have influenced outcomes negatively. A strength of
this review is that studies with relative small cohorts and
dated series were excluded.
Several further studies are needed in this field. First,
few studies of long-term outcomes on endocrine and
exocrine insufficiency and QoL have been published,
and this needs to be investigated in large prospective
series, evaluating clinicophysiological parameters and their
courses over time. Second, such studies should compare
outcomes with those following partial pancreatectomy,
especially for IPMN. Third, evidence-based guidelines
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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are needed for optimal management of endocrine and
exocrine insufficiency.
Acknowledgements
L.S. and T.F.S. contributed equally to this publication.
The authors acknowledge the work of F. S. van Etten
(clinical librarian) for her help with the literature search.
L.S. has received a grant from ZEALAND for studies on
management of postpancreatectomy diabetes. M.G.B. has
received a grant (number UVA2013-5842) from the Dutch
Cancer Society for studies on pancreatic cancer.
Disclosure: The authors declare no conflict of interest.
References
1 Almond M, Rob KJ, Hodson J, Sutcliffe R,
Marudanayagam R, Isaac J et al. Changing indications for a
total pancreatectomy: perspectives over a quarter of a
century. HPB (Oxford) 2015; 17: 416–421.
2 Müller MW, Friess H, Kleeff J, Dahmen R, Wagner M,
Hinz U et al. Is there still a role for total pancreatectomy?
Ann Surg 2007; 246: 966–975.
3 Chari ST, Yadav D, Smyrk TC, DiMagno EP, Miller LJ,
Raimondo M et al. Study of recurrence after surgical
resection of intraductal papillary mucinous neoplasm of the
pancreas. Gastroenterology 2002; 123: 1500–1507.
4 Andrén-Sandberg A, Ansorge C, Yadav TD. Are there
indications for total pancreatectomy in 2016? Dig Surg 2016;
33: 329–334.
5 Del Chiaro M, Rangelova E, Segersvärd R, Arnelo U. Are
there still indications for total pancreatectomy? Updates Surg
2016; 68: 257–263.
6 Hartwig W, Gluth A, Hinz U, Bergmann F, Spronk PE,
Hackert T et al. Total pancreatectomy for primary pancreatic
neoplasms: renaissance of an unpopular operation. Ann Surg
2015; 261: 537–546.
7 Griffin JF, Poruk KE, Wolfgang CL. Is it time to expand the
role of total pancreatectomy for IPMN? Dig Surg 2016; 33:
335–342.
8 Scholten L, van Huijgevoort NCM, Bruno MJ,
Fernandez-Del Castillo C, Satoi S, Sauvanet A et al.;
European Study Group on Cystic Tumours of the Pancreas
and the International Association of Pancreatology. Surgical
management of intraductal papillary mucinous neoplasm
with main duct involvement: an international expert survey
and case-vignette study. Surgery 2018; doi:10.1016/j.surg.
2018.01.025 [Epub ahead of print].
9 Scholten L. PROSPERO – International Prospective Register of
Systematic Reviews. http://www.crd.york.ac.uk/PROSPERO/
display_record.php?ID=CRD420016051093 [accessed
November 2018].
10 Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC,
Ioannidis JPA et al. The PRISMA statement for reporting
systematic reviews and meta-analyses of studies that evaluate
health care interventions: explanation and elaboration. J Clin
Epidemiol 2009; 62: e1–e34.
11 Suzuki S, Kajiyama H, Takemura A, Shimazaki J, Nishida K,
Shimoda M. The clinical outcomes after total
pancreatectomy. Dig Surg 2017; 34: 142–150.
12 WHO. Definition, Diagnosis and Classification of Diabetes
Mellitus and Its Complications. Part 1: Diagnosis and
Classification of Diabetes Mellitus; 1999.
http://apps.who.int/iris/bitstream/10665/66040/1/
WHO_NCD_NCS_99.2.pdf [accessed 2 February 2018].
13 American Diabetes Association. Diagnosis and classification
of diabetes mellitus. Diabetes Care 2016; 39(Suppl 1):
S13–S22.
14 Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting
the significance of changes in health-related quality-of-life
scores. J Clin Oncol 1998; 16: 139–144.
15 Wells GA, Shea B, O’Connell D, Peterson J, Welch V,
Losos M et al.; The Ottawa Hospital Research Institute. The
Newcastle–Ottawa Scale (NOS) for Assessing the Quality of
NonRandomised Studies in Meta-Analyses. http://www.ohri.ca/
programs/clinical_epidemiology/oxford.asp [accessed 15
February 2018].
16 Wan X, Wang W, Liu J, Tong T. Estimating the sample
mean and standard deviation from the sample size, median,
range and/or interquartile range. BMC Med Res Methodol
2014; 14: 135.
17 Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and
variance from the median, range, and the size of a sample.
BMC Med Res Methodol 2005; 5: 13.
18 Barbier L, Jamal W, Dokmak S, Aussilhou B, Corcos O,
Ruszniewski P et al. Impact of total pancreatectomy: short-
and long-term assessment. HPB (Oxford) 2013; 15: 882–892.
19 Casadei R, Monari F, Buscemi S, Laterza M, Ricci C,
Rega D et al. Total pancreatectomy: indications, operative
technique, and results: a single centre experience and review
of literature. Updates Surg 2010; 62: 41–46.
20 Casadei R, Ricci C, Taffurelli G, Guariniello A, Di Gioia A,
Di Marco M et al. Is total pancreatectomy as feasible, safe,
efficacious, and cost-effective as pancreaticoduodenectomy?
A single center, prospective, observational study.
J Gastrointest Surg 2016; 20: 1595–1607.
21 Crippa S, Tamburrino D, Partelli S, Salvia R, Germenia S,
Bassi C et al. Total pancreatectomy: indications, different
timing, and perioperative and long-term outcomes. Surgery
2011; 149: 79–86.
22 Crippa S, Pergolini I, Rubini C, Castelli P, Partelli S,
Zardini C et al. Risk of misdiagnosis and overtreatment in
patients with main pancreatic duct dilatation and suspected
combined/main-duct intraductal papillary mucinous
neoplasms. Surgery 2016; 159: 1041–1049.
23 Epelboym I, Winner M, DiNorcia J, Lee MK, Lee JA,
Schrope B et al. Quality of life in patients after total
pancreatectomy is comparable with quality of life in patients
who undergo a partial pancreatic resection. J Surg Res 2014;
187: 189–196.
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
on behalf of BJS Society Ltd.
L. Scholten, T. F. Stoop, M. Del Chiaro, O. R. Busch, C. van Eijck, I. Q. Molenaar et al.
24 Fujino Y, Matsumoto I, Ajiki T, Kuroda Y. Clinical
reappraisal of total pancreatectomy for pancreatic disease.
Hepatogastroenterology 2009; 56: 1525–1528.
25 Hata T, Ishida M, Motoi F, Sakata N, Yoshimatsu G,
Naitoh T et al. Clinical characteristics and risk factors for the
development of postoperative hepatic steatosis after total
pancreatectomy. Pancreas 2016; 45: 362–369.
26 Jamil LH, Chindris AM, Gill KR, Scimeca D, Stauffer JA,
Heckman MG et al. Glycemic control after total
pancreatectomy for intraductal papillary mucinous neoplasm:
an exploratory study. HPB Surg 2012; 2012: 381328.
27 Kitagawa M, Ikoma H, Ochiai T, Ishii H, Shiozaki A,
Kuriu Y et al. Total pancreatectomy for pancreatic
carcinoma: evaluation of safety and efficacy.
Hepatogastroenterology 2012; 59: 907–910.
28 Nikfarjam M, Low N, Weinberg L, Chia PH, He H,
Christophi C. Total pancreatectomy for the treatment of
pancreatic neoplasms. ANZ J Surg 2014; 84: 823–826.
29 Parsaik AK, Murad MH, Sathananthan A, Moorthy V, Erwin
PJ, Chari S et al.Metabolic and target organ outcomes after
total pancreatectomy: Mayo Clinic experience and meta-
analysis of the literature. Clin Endocrinol (Oxf) 2010; 73:
723–731.
30 Reddy S, Wolfgang CL, Cameron JL, Eckhauser F, Choti
MA, Schulick RD et al. Total pancreatectomy for pancreatic
adenocarcinoma: evaluation of morbidity and long-term
survival. Ann Surg 2009; 250: 282–287.
31 Shi HJ, Jin C, Fu DL. Impact of postoperative glycemic
control and nutritional status on clinical outcomes after
total pancreatectomy.World J Gastroenterol 2017; 23:
265–274.
32 Stauffer JA, Nguyen JH, Heckman MG, Grewal MS,
Dougherty M, Gill KR et al. Patient outcomes after total
pancreatectomy: a single centre contemporary experience.
HPB (Oxford) 2009; 11: 483–492.
33 Suzuki S, Miura J, Shimizu K, Tokushige K, Uchigata Y,
Yamamoto M. Clinicophysiological outcomes after total
pancreatectomy. Scand J Gastroenterol 2016; 51: 1526–1531.
34 Takami H, Fujii T, Kanda M, Suenaga M, Yamamura K,
Kodera Y. Preservation of the pyloric ring confers little
benefit in patients undergoing total pancreatectomy.World
J Surg 2014; 38: 1807–1813.
35 Watanabe Y, Ohtsuka T, Matsunaga T, Kimura H,
Tamura K, Ideno N et al. Long-term outcomes after total
pancreatectomy: special reference to survivors’ living
conditions and quality of life.World J Surg 2015; 39:
1231–1239.
36 Zakaria HM, Stauffer JA, Raimondo M, Woodward TA,
Wallace MB, Asbun HJ. Total pancreatectomy: short- and
long-term outcomes at a high-volume pancreas center.World
J Gastrointest Surg 2016; 8: 634–642.
37 Aaronson NK, Ahmedzai S, Bergman B, Bullinger M,
Cull A, Duez NJ et al. The European Organisation for
Research and Treatment of Cancer QLQ-C30: a
quality-of-life instrument for use in international clinical
trials in oncology. J Natl Cancer Inst 1993; 85:
365–376.
38 Scott NW, Fayers PM, Aaronson NK, Bottomley A, de
Graeff A, Groenvold M et al.; EORTC Quality of Life
Group. EORTC QLQ-C30 Reference Values. EORTC:
Brussels, 2008.
39 Jethwa P, Sodergren M, Lala A, Webber J, Buckels JA,
Bramhall SR et al. Diabetic control after total
pancreatectomy. Dig Liver Dis 2006; 38: 415–419.
40 Roberts KJ, Blanco G, Webber J, Marudanayagam R,
Sutcliffe RP, Muiesan P et al.How severe is diabetes after
total pancreatectomy? A case-matched analysis. HPB (Oxford)
2014; 16: 814–821.
41 Wu W, Dodson R, Makary MA, Weiss MJ, Hirose K,
Cameron JL et al. A contemporary evaluation of the
cause of death and long-term quality of life after
total pancreatectomy.World J Surg 2016; 40:
2513–2518.
42 Struyvenberg MR, Fong ZV, Martin CR, Tseng JF, Clancy
TE, Fernández-Del Castillo C et al. Impact of treatments on
diabetic control and gastrointestinal symptoms after total
pancreatectomy. Pancreas 2017; 46: 1188–1195.
43 Dresler CM, Fortner JG, McDermott K, Bajorunas DR.
Metabolic consequences of (regional) total pancreatectomy.
Ann Surg 1991; 214: 131–140.
44 Belyaev O, Herzog T, Chromik AM, Meurer K, Uhl W.
Early and late postoperative changes in the quality of life
after pancreatic surgery. Langenbecks Arch Surg 2013; 398:
547–555.
45 Billings BJ, Christein JD, Harmsen WS, Harrington JR,
Chari ST, Que FG et al. Quality-of-life after total
pancreatectomy: is it really that bad on long-term follow-up?
J Gastrointest Surg 2005; 9: 1059–1067.
Supporting information
Additional supporting information can be found online in the Supporting Information section at the end of the
article.
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
on behalf of BJS Society Ltd.
